TRIQUIN INJECTION

Indications

• African trypanosomiasis (sleeping sickness)
• Bovine trypanosomiasis
• Equine trypanosomiasis

Dosage

Children: Refer to the BNF for Children for specific pediatric dosing recommendations.

Adults: Refer to the BNF for specific dosing information. Doses may vary based on the condition being treated and the weight of the animal.

Mechanism of action

Quinapyramine exerts its pharmacological effects by inhibiting the activity of nucleic acid synthesis in trypanosomes, leading to cell death. Its action is thought to involve interference with mitochondrial function and the disruption of metabolic processes vital for the parasite's survival.

Pharmacodynamics

Quinapyramine demonstrates a selective toxicity towards trypanosomes, affecting their biochemical pathways while sparing host cells. The drug accumulates within the parasites, which enhances its effectiveness, especially in the presence of hypoxic conditions that further promote its uptake. The efficacy of quinapyramine is influenced by factors such as the stage of the disease and the specific trypanosome species involved.

Pharmacokinetics

Quinapyramine is well-absorbed after parenteral administration, with peak plasma concentrations occurring within hours. It has a moderate volume of distribution and is metabolized primarily in the liver. The elimination half-life varies based on the species treated and the route of administration, but it generally undergoes renal excretion. Careful monitoring of plasma levels may be necessary to avoid toxicity.

Pregnancy

There is limited information on the safety of quinapyramine in pregnancy. Caution is advised.

Breast-feeding

It is not known whether quinapyramine is excreted in human milk. Caution is recommended.

Storage

Store at room temperature, away from light and moisture.

Formulations

• {'formulation': 'Quinapyramine', 'type': 'Injection', 'strength': 'available in various strengths'}